癌症免疫疗法的进展:历史回顾、当前发展及未来方向。

Advances in cancer immunotherapy: historical perspectives, current developments, and future directions.

作者信息

Zhang Meiyin, Liu Chaojun, Tu Jing, Tang Min, Ashrafizadeh Milad, Nabavi Noushin, Sethi Gautam, Zhao Peiqing, Liu Shijian

机构信息

Department of Surgical Oncology, Harbin Medical University Cancer Hospital, Harbin, China.

Department of Breast Surgery, Henan Provincial People's Hospital; People's Hospital of Zhengzhou University; People's Hospital of Henan University, Zhengzhou, Henan, 450003, China.

出版信息

Mol Cancer. 2025 May 7;24(1):136. doi: 10.1186/s12943-025-02305-x.

Abstract

Cancer immunotherapy, encompassing both experimental and standard-of-care therapies, has emerged as a promising approach to harnessing the immune system for tumor suppression. Experimental strategies, including novel immunotherapies and preclinical models, are actively being explored, while established treatments, such as immune checkpoint inhibitors (ICIs), are widely implemented in clinical settings. This comprehensive review examines the historical evolution, underlying mechanisms, and diverse strategies of cancer immunotherapy, highlighting both its clinical applications and ongoing preclinical advancements. The review delves into the essential components of anticancer immunity, including dendritic cell activation, T cell priming, and immune surveillance, while addressing the challenges posed by immune evasion mechanisms. Key immunotherapeutic strategies, such as cancer vaccines, oncolytic viruses, adoptive cell transfer, and ICIs, are discussed in detail. Additionally, the role of nanotechnology, cytokines, chemokines, and adjuvants in enhancing the precision and efficacy of immunotherapies were explored. Combination therapies, particularly those integrating immunotherapy with radiotherapy or chemotherapy, exhibit synergistic potential but necessitate careful management to reduce side effects. Emerging factors influencing immunotherapy outcomes, including tumor heterogeneity, gut microbiota composition, and genomic and epigenetic modifications, are also examined. Furthermore, the molecular mechanisms underlying immune evasion and therapeutic resistance are analyzed, with a focus on the contributions of noncoding RNAs and epigenetic alterations, along with innovative intervention strategies. This review emphasizes recent preclinical and clinical advancements, with particular attention to biomarker-driven approaches aimed at optimizing patient prognosis. Challenges such as immunotherapy-related toxicity, limited efficacy in solid tumors, and production constraints are highlighted as critical areas for future research. Advancements in personalized therapies and novel delivery systems are proposed as avenues to enhance treatment effectiveness and accessibility. By incorporating insights from multiple disciplines, this review aims to deepen the understanding and application of cancer immunotherapy, ultimately fostering more effective and widely accessible therapeutic solutions.

摘要

癌症免疫疗法,包括实验性疗法和标准治疗方法,已成为一种利用免疫系统抑制肿瘤的有前景的方法。包括新型免疫疗法和临床前模型在内的实验策略正在积极探索中,而诸如免疫检查点抑制剂(ICI)等成熟疗法则在临床环境中广泛应用。这篇综述全面审视了癌症免疫疗法的历史演变、潜在机制和多种策略,突出了其临床应用和正在进行的临床前进展。该综述深入探讨了抗癌免疫的基本组成部分,包括树突状细胞激活、T细胞致敏和免疫监视,同时也探讨了免疫逃逸机制带来的挑战。详细讨论了关键的免疫治疗策略,如癌症疫苗、溶瘤病毒、过继性细胞转移和ICI。此外,还探讨了纳米技术、细胞因子、趋化因子和佐剂在提高免疫疗法的精准度和疗效方面的作用。联合疗法,特别是那些将免疫疗法与放疗或化疗相结合的疗法,具有协同潜力,但需要谨慎管理以减少副作用。还研究了影响免疫治疗结果的新出现因素,包括肿瘤异质性、肠道微生物群组成以及基因组和表观遗传修饰。此外,分析了免疫逃逸和治疗抗性的分子机制,重点关注非编码RNA和表观遗传改变的作用以及创新的干预策略。这篇综述强调了近期的临床前和临床进展,特别关注旨在优化患者预后的生物标志物驱动方法。免疫疗法相关毒性、实体瘤疗效有限和生产限制等挑战被突出为未来研究的关键领域。提出个性化疗法和新型递送系统的进展作为提高治疗效果和可及性的途径。通过整合多学科的见解,这篇综述旨在加深对癌症免疫疗法的理解和应用,最终促进更有效且广泛可及的治疗方案。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4479/12057291/bbd3a7d3d06c/12943_2025_2305_Fig1_HTML.jpg

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索